Marshall Wace, LLP Synaptogenix, Inc. Transaction History
Marshall Wace, LLP
- $63.3 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding SNPX
# of Institutions
25Shares Held
955KCall Options Held
0Put Options Held
0-
Jim Simons Renaissance Technologies LLC | New York, Ny401KShares$1.63 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA154KShares$627,1520.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il83.5KShares$339,1880.0% of portfolio
-
Two Sigma Securities, LLC New York, NY83.4KShares$338,6400.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA68.5KShares$278,1990.0% of portfolio
About Synaptogenix, Inc.
- Ticker SNPX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 6,840,630
- Market Cap $27.8M
- Description
- Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodeg...